BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Leal JL, Solomon B, John T. Finding chinks in the osimertinib resistance armor. Transl Lung Cancer Res 2020;9:2173-7. [PMID: 33209638 DOI: 10.21037/tlcr-20-579] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Wang L, Ding X, Wang K, Sun R, Li M, Wang F, Xu Y. Structure-based modification of ortho-amidophenylaminopyrimidines as a novel mutant EGFR inhibitor against resistant non-small cell lung cancer. Journal of Molecular Structure 2022. [DOI: 10.1016/j.molstruc.2022.134499] [Reference Citation Analysis]
2 McLean LS, Faisal W, Parakh S, Kao SC, Lewis CR, Chin MT, Voskoboynik M, Itchins MJ, Jennens RR, Broad AR, Morris TA, Solomon BJ. Standard-Dose Osimertinib in EGFR-Mutated Non-Small-Cell Lung Adenocarcinoma With Leptomeningeal Disease. JCO Precis Oncol 2021;5:561-8. [PMID: 34994604 DOI: 10.1200/PO.20.00464] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Lim JU. Management of Oligometastasis and Oligoprogression in Patients with Epidermal Growth Factor Receptor Mutation-Positive NSCLC in the Era of Third-Generation Tyrosine Kinase Inhibitors. Clin Lung Cancer 2021:S1525-7304(21)00056-5. [PMID: 33849807 DOI: 10.1016/j.cllc.2021.03.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]